- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06686394
Tutkimus patritumabi derukstekaanista muiden syöpälääkkeiden kanssa potilailla, joilla on HER2-positiivinen rintasyöpä, joka on levinnyt ja jota ei voida poistaa kirurgisesti (MK-1022-009)
HERTHENA-Breast-01: Vaihe 1b/2, monikeskus, avoin, annoksenhakututkimus patritumabiderukstekaanin turvallisuuden ja kasvaimia estävän vaikutuksen arvioimiseksi osallistujilla, joilla on HER2-positiivinen, ei-leikkauksellinen paikallisesti edennyt rintasyöpä tai metastaattinen rintasyöpä
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Toll Free Number
- Puhelinnumero: 1-888-577-8839
- Sähköposti: Trialsites@msd.com
Opiskelupaikat
-
-
-
Seoul, Etelä -Korea, 03080
- Rekrytointi
- Seoul National University Hospital ( Site 0030)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 82-2-2072-0850
-
Seoul, Etelä -Korea, 05505
- Rekrytointi
- Asan Medical Center ( Site 0031)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +82-2-1688-7575
-
-
-
-
-
Haifa, Israel, 3109601
- Rekrytointi
- Rambam Health Care Campus ( Site 0011)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 04-7776234
-
Petah Tikva, Israel, 4941492
- Rekrytointi
- Rabin Medical Center ( Site 0012)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +972-505533121
-
Ramat Gan, Israel, 5265601
- Rekrytointi
- Sheba Medical Center ( Site 0010)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japani, 467-8602
- Rekrytointi
- Nagoya City University Hospital ( Site 0020)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +81-52-851-5511
-
-
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L 2V7
- Rekrytointi
- Kingston General Hospital ( Site 0061)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 6135336541
-
Toronto, Ontario, Kanada, M5G 2M9
- Rekrytointi
- Princess Margaret Cancer Centre ( Site 0001)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrytointi
- Jewish General Hospital ( Site 0003)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 514-340-8222
-
Montreal, Quebec, Kanada, H2X 3E4
- Rekrytointi
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: (514)890-8000 x20737
-
-
-
-
Camden
-
London, Camden, Yhdistynyt kuningaskunta, NW1 2PG
- Rekrytointi
- University College London Hospital ( Site 0041)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Yhdistynyt kuningaskunta, G12 0YN
- Rekrytointi
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +441413017000
-
-
London, City of
-
London, London, City of, Yhdistynyt kuningaskunta, EC1A 7BE
- Rekrytointi
- St Bartholomew s Hospital ( Site 0040)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: +442073777000
-
-
-
-
Colorado
-
Aurora, Colorado, Yhdysvallat, 80045
- Rekrytointi
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Rekrytointi
- Dana-Farber Cancer Institute ( Site 0050)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Yhdysvallat, 08901
- Rekrytointi
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Yhdysvallat, 29605
- Rekrytointi
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22031
- Rekrytointi
- Inova Schar Cancer Institute ( Site 0051)
-
Ottaa yhteyttä:
- Study Coordinator
- Puhelinnumero: 571-472-4724
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Muut nimet:
Trastuzumab administered via IV infusion
Muut nimet:
Trastuzumab biosimilar administered via IV infusion
Muut nimet:
|
|
Kokeellinen: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Muut nimet:
Trastuzumab administered via IV infusion
Muut nimet:
Trastuzumab biosimilar administered via IV infusion
Muut nimet:
Pertuzumab administered via IV infusion |
|
Kokeellinen: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Muut nimet:
Trastuzumab administered via IV infusion
Muut nimet:
Trastuzumab biosimilar administered via IV infusion
Muut nimet:
Tucatinib administered as oral tablets |
|
Kokeellinen: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Muut nimet:
Trastuzumab administered via IV infusion
Muut nimet:
Trastuzumab biosimilar administered via IV infusion
Muut nimet:
Pertuzumab administered via IV infusion |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Aikaikkuna: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Aikaikkuna: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Aikaikkuna: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Aikaikkuna: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Aikaikkuna: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Aikaikkuna: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Aikaikkuna: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Aikaikkuna: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Aikaikkuna: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Opintojohtaja: Medical Director, Merck Sharp & Dohme LLC
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Ihosairaudet
- Rintojen sairaudet
- Iho- ja sidekudostaudit
- Rintojen kasvaimet
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Vasta -aineet, monoklonaalinen, humanisoitu
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Trastutsumabi
- pertuzumabi
- tukatinibi
- patritumab deruxtecan
- Ogivri
- Ontruzant
Muut tutkimustunnusnumerot
- 1022-009
- MK-1022-009 (Muu tunniste: MSD)
- jRCT2041250022 (Rekisterin tunniste: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Rekisterin tunniste: EU CT)
- U1111-1346-4321 (Rekisterin tunniste: UTN)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .